-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 AF8tAQNQnOo7f+e6mkqKl7hTs324PVwIhp+W6J0sRaYpDTHUNuGZ7k44alkEc1ap
 eadGHOvh0ApZRrd06Cxlbw==

<SEC-DOCUMENT>0001193125-10-187263.txt : 20100812
<SEC-HEADER>0001193125-10-187263.hdr.sgml : 20100812
<ACCEPTANCE-DATETIME>20100812161254
ACCESSION NUMBER:		0001193125-10-187263
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20100812
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20100812
DATE AS OF CHANGE:		20100812

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ARROWHEAD RESEARCH CORP
		CENTRAL INDEX KEY:			0000879407
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH [8731]
		IRS NUMBER:				460408024
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			0930

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-21898
		FILM NUMBER:		101011308

	BUSINESS ADDRESS:	
		STREET 1:		201 SOUTH LAKE AVENUE
		STREET 2:		SUITE 703
		CITY:			PASADENA
		STATE:			CA
		ZIP:			91101
		BUSINESS PHONE:		626-304-3400

	MAIL ADDRESS:	
		STREET 1:		201 SOUTH LAKE AVENUE
		STREET 2:		SUITE 703
		CITY:			PASADENA
		STATE:			CA
		ZIP:			91101

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	INTERACTIVE GROUP INC
		DATE OF NAME CHANGE:	20020509

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	INTERACTIVE INC
		DATE OF NAME CHANGE:	19940224
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML><HEAD>
<TITLE>Form 8-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="line-height:0px;margin-top:0px;margin-bottom:0px;border-bottom:0.5pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P> <P STYLE="margin-top:4px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>UNITED STATES </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>SECURITIES AND EXCHANGE COMMISSION </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>WASHINGTON, D.C. 20549 </B></FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>FORM 8-K </B>
</FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="4"><B>CURRENT REPORT </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>PURSUANT TO SECTION 13 OR 15(D) OF THE </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>SECURITIES EXCHANGE ACT OF 1934 </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>Date of Report (Date of earliest event reported): August&nbsp;12, 2010 </B></FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="6"><B>Arrowhead Research Corporation </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(Exact name of registrant as specified in its charter) </B></FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>0-21898 </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Commission </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>File Number) </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="50%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Delaware</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>46-0408024</B></FONT></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(State or other jurisdiction</B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>of incorporation)</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(IRS Employer</B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Identification No.)</B></FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>201 South Lake Avenue, Suite 703, Pasadena, CA 91101 </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Address of principal executive offices) (Zip Code) </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Registrant&#146;s telephone number, including area code (626)&nbsp;304-3400 </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the
following provisions: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b) </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pre-commencement communications pursuant to Rule 13e-4 (c)&nbsp;under the Exchange Act (17 CFR 240.13e-4(c) </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="line-height:3px;margin-top:0px;margin-bottom:0px;border-bottom:0.5pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Item&nbsp;2.02.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Results of Operations and Financial Condition. </B></FONT></TD></TR></TABLE>
<P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">On August&nbsp;12, 2010, Arrowhead Research Corporation announced and commented on its financial results for the quarter ended June&nbsp;30, 2010. A copy
of the press release is attached hereto as Exhibit&nbsp;99.1. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>In accordance with General Instruction B.2 of Form 8-K, the information in
this Current Report on Form 8-K, including Exhibit&nbsp;99.1, shall not be deemed &#147;filed&#148; for purposes of Section&nbsp;18 of the Securities Exchange Act of 1934, as amended (the &#147;<U>Exchange Act</U>&#148;), or otherwise subject to the
liability of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, except as expressly set forth by specific
reference in such filing to this Current Report on Form 8-K. </I></FONT></P> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Item&nbsp;9.01.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Financial Statements and Exhibits. </B></FONT></TD></TR></TABLE>
<P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">(d)&nbsp;Exhibits </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="94%"></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Exhibit</B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000;width:25pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>No.</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:39pt"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Description</B></FONT></P></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">99.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Press Release, dated August&nbsp;12, 2010.</FONT></TD></TR></TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>SIGNATURES </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Date: August&nbsp;12, 2010 </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0">

<TR>
<TD WIDTH="6%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2">ARROWHEAD RESEARCH CORPORATION</FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">By:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">/<SMALL>S</SMALL>/&nbsp;&nbsp;&nbsp;&nbsp;K<SMALL>ENNETH</SMALL> A.
M<SMALL>YSZKOWSKI&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</SMALL></FONT></P></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Kenneth A. Myszkowski</B></FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Chief Financial Officer</B></FONT></TD></TR></TABLE></DIV>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>dex991.htm
<DESCRIPTION>PRESS RELEASE
<TEXT>
<HTML><HEAD>
<TITLE>Press Release</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Exhibit 99.1 </B></FONT></P>
 <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center">

<IMG SRC="g48281g14u98.jpg" ALT="LOGO"> </P>
 <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="50%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>PRESS RELEASE</B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px; margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">August&nbsp;12, 2010</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Investor Relations Contact:</B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">Brandi Floberg</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">The
Piacente Group, Inc.</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">212-481-2050</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">ir@arrowres.com</FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:24px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>ARROWHEAD REPORTS FISCAL 2010 THIRD QUARTER FINANCIAL RESULTS </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>PASADENA, Calif. &#150; August&nbsp;12, 2010 &#150; Arrowhead Research Corporation (NASDAQ: ARWR) </B>today announced financial results for its fiscal
2010 third quarter ended June&nbsp;30, 2010. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;In the third quarter, we continued to advance our late-stage subsidiaries and build on the
momentum we began early in the calendar year,&#148; said Christopher Anzalone, Arrowhead&#146;s CEO. &#147;In-line with our expectations, Calando&#146;s first-in-class Phase I interim results continue to generate interface opportunities with
potential partners. Also, Unidym secured additional joint development agreements with two large partners. With the completion of our successful $8.7 million financing, we have the capital to support the disciplined implementation of Calando&#146;s
and Unidym&#146;s strategies and to invest in future initiatives designed to accelerate growth. We have already selected, for diligence and potential acquisition, an exciting technology that addresses the large, underserved obesity market
opportunity. With these achievements, we are making important strategic advancements to build a robust and unique portfolio of nanomedicine companies.&#148; </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>THIRD QUARTER FISCAL 2010 AND RECENT COMPANY HIGHLIGHTS: </B></FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Business highlights:</B> </FONT></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Arrowhead secured $8.7 million in financing through a registered direct offering of stock and warrants. </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Arrowhead rejoined the Russell Microcap Index. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Presented interim data from majority-owned subsidiary Calando Pharmaceuticals, Inc.&#146;s Phase I human trial of its anti-cancer siRNA therapeutic,
CALAA-01, at the American Society for Clinical Oncology Annual (ASCO) Meeting. </FONT></P></TD></TR></TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Unidym entered joint development agreements with Toyko Electron and Guardian Glass, two global companies developing products for the display industry.
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Arrowhead signed an option agreement with The University of Texas MD Anderson Cancer Center to negotiate a license in a defined field to a class of
compounds that is believed to kill fat tissue by specifically targeting the blood vessels that supply it. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Arrowhead added two world-class scientists to its Scientific Advisory Board, Nobel Prize winner Dr.&nbsp;Lee Hartwell and former FDA Commissioner
Dr.&nbsp;Andrew von Eschenbach. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Leonardo Biosciences obtained $2.5 million in financing from the Texas Emerging Technology Fund and recruited Dr.&nbsp;Bruce Given as its Chief
Executive Officer. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B></B><B>Financial highlights:</B> </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Decreased consolidated quarterly operating expenses by 53% versus the prior year&#146;s quarter from $4.9 million to $2.3 million.
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Decreased, on a consolidated basis, cash used in operating activities from $12.7 million in the first nine months of 2009 to $5.2 million in the first
nine months of 2010. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>SELECTED FISCAL 2010 THIRD QUARTER FINANCIAL RESULTS </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">For the quarter ended June&nbsp;30, 2010, Arrowhead reported revenue of $134,000, compared with $2.6 million in the quarter ended June&nbsp;30, 2009. The
prior period revenue included $2.4 million related to revenue from a license agreement between Calando and Cerulean Pharma, Inc. which was not repeated in the current period. Revenue at Unidym was comparable to the prior period. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total operating expenses for the quarter ended June&nbsp;30, 2010 were $2.3 million, a decrease of $2.6 million from $4.9 million during the quarter
ended June&nbsp;30, 2009. The significant reduction in operating expenses was a result of measures undertaken by management during 2009 to streamline its businesses and better align its cost structure with its capital resources. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Net loss for the quarter ended June&nbsp;30, 2010 was $0.4 million, or $0.01 per share based on 64.6&nbsp;million weighted average shares outstanding.
This compares with a net loss of $2.5 million, or $0.6 per share based on 43.4&nbsp;million weighted average shares outstanding, for the quarter ended June&nbsp;30, 2009. In addition to the change in revenue and operating expenses, a non-cash gain
of $1.6 million was recorded as the change in value of a derivative liability. </FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>CONFERENCE CALL </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Management will host a conference call on Thursday, August&nbsp;12, 2010, at 4:30 p.m. Eastern time/1:30 p.m. Pacific time. To participate in the
conference call, please dial 877-407-4134 toll free from the US or Canada, or 201-689-8430 from outside the US or Canada. Investors may also access a live audio webcast of this conference call on the Company&#146;s website at
www.arrowheadresearch.com. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">A replay of the webcast will be available approximately two hours after the conclusion of the call. The webcast
replay will remain available for 90 days. An audio replay will also be available approximately two hours after the conclusion of the call and will be made available until Thursday, August&nbsp;19, 2010. The audio replay can be accessed by dialing
877-660-6853 toll free from the US or Canada, or 201-612-7415 outside the U.S. and Canada, and entering account number 356 followed by access ID number 354878. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>About Arrowhead Research Corporation </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Arrowhead Research Corporation (www.arrowheadresearch.com) (NASDAQ: ARWR) is a nanotechnology company commercializing new technologies in the areas of
life sciences and electronics. Arrowhead is seeking to build value for shareholders through the progress of its subsidiaries and investments. Currently, Arrowhead is focused primarily on its two majority owned subsidiaries; Unidym, a leader in
carbon nanotube technology for electronic applications, and Calando, at the forefront of clinical application of RNAi delivery technology. Arrowhead also has minority investments in two privately held nanobiotech companies. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>This news release contains forward-looking statements within the meaning of the &#147;safe harbor&#148; provisions of the Private Securities Litigation
Reform Act of 1995. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various
factors and uncertainties, including the future success of our scientific studies, our ability to successfully develop products, rapid technological change in our markets, changes in demand for our future products, legislative, regulatory and
competitive developments, the financial resources available to us, and general economic conditions. For example, there can be no assurance that Arrowhead or its subsidiaries will be able to sustain operations for expected periods, that we will be
able to sustain targeted levels of expense reductions or that any of these entities will be successful in obtaining additional funding needed to sustain operations. Additionally, there can be no assurance that the company will successfully acquire
new programs or compounds, as may be currently expected. Arrowhead Research Corporation&#146;s most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q discuss some of the important risk factors that may affect our
business, results of operations and financial condition. We assume no obligation to update or revise forward-looking statements to reflect new events or circumstances. </I></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I># # # </I></FONT></P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g48281g14u98.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g48281g14u98.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````/```_^X`#D%D
M;V)E`&3``````?_;`(0`!@0$!`4$!@4%!@D&!08)"P@&!@@+#`H*"PH*#!`,
M#`P,#`P0#`X/$`\.#!,3%!03$QP;&QL<'Q\?'Q\?'Q\?'P$'!P<-#`T8$!`8
M&A41%1H?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?
M'Q\?'Q\?'Q\?_\``$0@`50"K`P$1``(1`0,1`?_$`)H``0`!!0$!````````
M```````$`0,%!@<""`$!``,!`0$```````````````$"`P0%!A```0,#`P($
M`P0%"0D``````@$#!``1!1(3!B$',4$B%%$R%6%"(Q9Q@3,D")%28J+20Y0E
M5;'!@E/3-74F%Q$``@(!`P0#``$%`0````````$1`@,A$@0Q05$382(4D7&!
MP=%"<O_:``P#`0`"$0,1`#\`^J:`4`H!0"@%`*`4`H#P\X+8$9?**77]5"+-
M)2S7&^9`4O;7'RDC+T1[:<O?[1T_[ZB3B7.JW#5OX-C0Q44).HJGC5D=DZ?!
M[J"PH!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`HJV2B"-([@Y+(NH.*AP9;[1(A
M276H:2VB1?`%U$"73Q6J6L>;S[6:VU3_`(DT7Z5/M_V:7?\`\*U_U*I)X_Y;
MKMK_`.'_`+.@\"R>0.*N,FPY3/MT16'7XB16]OPT"B$:7&M*,]K@Y+);;)_Q
M!N-6/0%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0&$Y9R>!QW$.3Y:JJWT,M#;6
M9KY#?X>-19P4R9-JU.&',XQ/G$2IEWI<IR]D>:N3CB^"(@_%:YHEGCO#2]NY
MTR7VOQ`\6&,(RBE,*4K4#J;YFH]6M5M-K=$K;8H.ZW#KL@YK`RW%\;D&9D?Z
MJ$F,XABA/-6N*]1)%3S\%K*$CEICK5RMQWCCF?@Y[$L9*&OX3J>H%MJ`T^82
MMYI72CU:65E*,I0L*`4`H!0"@%`*`4`H!0"@%`*`4`H`JHB=>E`<=YIENY$W
M./)B($QG&1_PX^EH51RWBYZK_-Y?95&K,YLEK=C-]L\;S!U]^?R,GFFF_P`.
M+$>!L5(EZJXMA\!\$^VBIY+XI[G1EJQL<O[C8WG$7)-R^/$^_"DI^)'8!LMI
MP?/J/RE_MJ&F<]U9/0L=O\OW`B9H8^<@3',;*32KKC8HC)^*'Z;=%\%J$F,=
MK3#.L(MTJYT"@%`*`4`H!0"@%`*`4`H!0"@%`4+PH#GW>'*\E#`IB>.P)$R5
M/N,I]A$799^\E[IZC\$^R]:8ZIO4YN3=JL+N<4P?;OF^0RL6'+Q\C'Q'31)$
MQ^P@VVG4EOJ\;>%:NM4CCQU;>I]/8J-C8$"/CH1`+$<$;:;0D5;"E<\,])1$
M23K^506DQ7(<;B\UB9>)G.`C,D%`O4B$)>(DG7Q%>M2DRMX::9\PY'M_W`B3
MI$4,7*EMLF0!)9LK;@HO0Q+5X+7355CJ>9:ET]$=_P"UV8Y!,XXW%Y%">AY.
M%9I2?1$5YM$]#B65>MNA?;6.2NNAW8+MJ'U-U2LSH%`*`4`H!0"@%`*`4`H!
M0"@%`4)+I:H8/B/NS+S3?</.IF2()7NCV]6H15A%LUHO:XZ+6KV>,JNI\[R:
MV=W,FH^_3_F_UEKHA&&QG2?X=Y0N=U<:*'==F3TNJ_W2UR<M)4T.W@U:R?!]
M@VKR$SW#XK[TS!#NGR(-RUI(I;5:WX85[7&JMJ/G^76SR,TGWZ>&[_6K?:D<
MOK9T+L/)S3G<S$_2U,P0B3($-R!(RBNO6J=$ZVM?SKGY*KL.SA4LKRC[(2O(
M/>@K0"@%`*`4`H!0"]`4U)42"MZD"]`+TD%-25$@*J5+!"FX7#SW$<FP(\HP
M2PF^T#BHGP131;5*LRKHF1ORGQ;_`$:!_AF?[--S\D;:^$7HG'\%#?21$QL6
M.^**@NM,-MFB+XV(11:;F2J*>AD%6JEC&O\`'./27C?DXN(^^XMW'7([1F2_
M%2(55:LFRNU>"W^4^+?Z-!_PS/\`9IO?D;*^$2H.)Q4!26#"8B:_GV&@;U6^
M.A$O4;FR55+H3/.A)6Z4`O0"@%`4U)>U")*W2B)%Z`P7-N40^+<6R.=E=6X3
M2FVWYFZO1L$^TC5$JU*;G!2]]JDT#M3SWE;^?D<9YG*9?RDJ(SE,6\R@`.TX
M-W(]@LBDTOCY^-;YL-83KV,,.9S%C(8'O="RTV.RF!R$>'+>EQH^0+:-DG80
MJ3@%H)2#Y>BDEJI;CM%UR%)XP/?;$9(&I,W$3<3BY$21.CY*1M&R341;.WVB
M-1*Z=$+QJ;8&D%G1<A=ZXCA8YZ?@,CB\7F3VL3DY*-;3SA?LA)!(C:W/NJ:)
M3T>&A^CX+<_OSQV%P^/R-V!*UO37<>YBTT+);=8NKJFB+IL`CJ7]-2N/9N"'
MR*P6NXO=M(>,RL+CFXN3CX<<P&31&R88!TA1I#$[ZB-%Z):F+#+U(RYTEH2^
M,]W&W9>,Q'(<5,P\Z=!67'F2D:)F0++>MTQ5DBT]+E942HO@?;74FF==]-#U
M@.\L/D$^,UBL/(>QTI[99R)OQ&D5$6VO8-U']/3^9>E^.Z]6*\A6[$?)]\(V
M&>_SK`RH,07D8>D^XA/*WJ+2A$RT\3MO^&H6!M:$O.D]23R/NRTW+RV(X]BI
MN9R&,CJ<V3%%L68Q$WK!3)XA0E1/59+U->/TGH1;/U@G=L>0Y?-]K\9F\F_[
MC)R(SKCS^@0U$!&B+I%$'[J>54RU5;PBV.[=).,8KNWRN3QES*2^X3,3,BKN
MUA"QP.*9`2HV&L`_O+5V6P)6C:<E<[:EV.G,=Y2@X3C[68QCKG+,O$26]BF5
M;8VP1513,Y)M@&JW05*]<WHEMKH='OA*>I?R/>N#`#%LNX>0N5RJ/&SCQD0_
M2VP6E3*0KNQU7P%#O45X[:;[%K<A+0DR^[^.QW&QS66QLB$4B4D/'P4=CON2
M752Z:#9<-H4^*D26J*X6W"9+S)*8+D3N=-DXF;D!XY(0H9M"L=)D`B)'55%/
M6+RMB@6ZZE2_E4VQ0^HKFGL1L/WHQ4^;D,?*QLB#D8$%W)#')R.^CS+**1Z'
M&#<!"Z>"K2V!PG)%<Z;:(^'[[867&*;DL5-P^/7'%E6)KZ-N-NQQ/;L*LD=C
M4EZ"O6I?'<P0N0H*9#N=R"9Q3*Y.#QS(8AH,<_,@Y>8C&W<`U-JK2&1^KQ2X
MU%<7VAON0\OUE+L6^$]W9,D>,XSD6)FPIN=CA[/*NHRL>4\C:&1"C1*H:_%+
MBE3DPQ,/H33/HI[G4+K\*YY9T0C4>?=O@YFYBHT^8H86%)25.QR"J^[44L`$
M:*BB*?96E,FW^IG?%N,--[&\8CY7$YCBR)@,EBY*/JZWK>%YNUB9,3/Y23X5
M=<BT-/4KZ*S*,YPG@0\8XQ+P:2_<^ZD2I"/J&C3[I572@W7Y;_&JY,NZTC'C
MVU@LX#MGC\?VX_(\Y]9L,F7H[TA!VR(7B4KHB*ME352V5NVXE8DJ[3!QNSV7
M>^D0,[R5W*<?P+S3^.Q_MVVC(F.C*/NC=30$Z=$2K^Y:M+J9+CO1-]"0'9;$
M?GG(\D>E$]"G`^J8<@3:;?EM(T^\*W\3%/A4_H>U5\%OSK<[>2!ANP\;'<.Y
M%@"RSDF5GFVX_P!2=;139CL(B,M(.KJ@V^-3;DMV3CH17CI5:\F=R7;*/D<Q
MQN<_,56<!">@.1M'[<'V49)=5_1T2LZYFD].I:V"6G\&`X]V)#`S(J0\G'=Q
M\1Q2;%_'QRF(!7]*2TL:$E_25KI6EN2WV*5XL=S%N_PX*6&<PS>;8]H;NZ,I
MS'LG.^?78I6I#7K5_P!6LP5_+IU-DG=I\DWD\I.XYR)S$)G``<O%*.W):=(&
M]K6&M1(%4?MK%<A0DUT+/`Y;3ZFR<,X>G&N%0^,C)]RD-DV$DJ.A2UJ2WTW7
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M$GOE(B#$2&Y*!$;-;+J$T3U65%ZUG[/MN-/7]=ICF^W/+RPLO`S^6E.P[\)V
M`TRY#9!P!(-#9DX"CJ4$_EJWM6Z4M9*^E[8;T@DGVP0OR3_F"_\`IUK?AI^\
M6:1KKU]'A?SJ/;U^2WJZ?!O5EK$V*U(%J`6H!:@%J`U[EN:DXSZ<+,AF($R1
MLO2I"7!L-LCOU(4ZJ-NJU6S9R<K,Z;4G$LP[G+9B!`#ZO!1J3)DLN9/0HLH+
M`(0#ZC0=2KT546WPJ-3EMRK+:MRU;UCP6'.8YI8H)&=:EF61=B))C-(XCC3;
M&[J`-:(I7Z?-269OF9(TU^T:+MH49YAR.3#QBL")O3I$D+@T*N*TR.H55M7$
M0#_G"I=*B6/V976L+5M]B^7)N0,R8,/*RHF'=>8?><>D"-ET.H#8I^)I12!;
MJEZE-FGZ,DU5FJZ>",?-\V4.`XVHN[WO5?=C,[RD$0T$3;!3'HJ=5LM-S,7S
M<FVL=?M.G@I)[A99K&8TVV!DSW&UDS08;-X=A#5`%-I30#<%.EULEEJ-S+OG
M7VU:4N&V9@<SEY6>@,0IS)8W(1CF-$K-R0`($TWU=;Z_A5YU.CW9'DJJOZV4
M]""?,,@116W9<6`V_+G,.2WQ]`C%*S:>H@347Z:JWJ8/EW;2G;+MV\'AKF.>
M-AA80QLDZN0?BHK?H%]EAK<NVNHA0U_3:HEBO-R:1]GN?\)&>XIR$\VU/?TJ
M#<>4K#0&!-N"@M@JB8E]Y"):M4Z^)G>3<VHBW^$9^U6.P6H!0"R4(@4)%J$0
M*$B@%`*`4!%G_3MO]_V=GI^WTZ+^7S]+U#*7VQ]HCY(SGY?]H&Y[3V=_P]6U
MM:OZ-_3>I,WZHUV[?[%Z/]*VV_;;&WJ79VM%M=NNG3TO;X4+5VQI$?!5KZ=N
M)M;.O45M.F^O[_A][XT)6WM!YR'T?T?4/;_T-_1^NVNB&39IN@],_3=+.QLZ
M;%L;>FUOO:+>7QM0A;-(@1/IVDO:;-OO[6GPZ^.G]=":[8T/37L+M[6UJTKM
M:--]/GIMY?HIW)KM[%B3]$VOWKVVSK6V[MZ=?WOFZ7IW*7]<:P7(OTO;:]ML
M;=UV=K1IO;U:=/G;QM4:%J;?^20UL7<VM.K5^+IM\UD^:WG:I)K&L%VA<4`H
'!0"@%`?_V3\_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
